Association of Target Therapy Gene Expression with Metastasizing of Clear-Cell Renal Cell Carcinoma
- Autores: Apanovich N.V.1, Peters M.V.2, Apanovich P.V.1, Markova A.S.2, Kamolov B.S.2, Matveev V.B.2,3, Karpukhin A.V.1
-
Afiliações:
- Research Center for Medical Genetics
- N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
- M. V. Lomonosov Moscow State University
- Edição: Volume 166, Nº 2 (2018)
- Páginas: 257-259
- Seção: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/240942
- DOI: https://doi.org/10.1007/s10517-018-4327-z
- ID: 240942
Citar
Resumo
We analyzed association of the levels of VEGFA, RAF1, and mTOR gene expression in the tissue of clear-cell renal cell carcinoma (ccRCC) with tumor metastasizing. Significant association with metastases was found only for VEGFA gene: OR=6.641, 95%CI=2.111-20.696. The risk of metastasis associated with reduced expression of VEGFA gene — 2.467, 95%CI=1.238-4.915. An association of VEGFA gene expression with the time to the metastasis appearance was revealed (p=0.0005). Reduced expression of the VEGFA gene is associated with reduction of the time to metastasis appearance; the median of this time is shifted from 46 to 2 months. Analysis of tumor samples with reduced expression of the VEGFA gene revealed association of increased expression of RAF1 (p=0.003) and mTOR genes (p=0.038) with metastasis.
Sobre autores
N. Apanovich
Research Center for Medical Genetics
Email: karpukhin@med-gen.ru
Rússia, Moscow
M. Peters
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: karpukhin@med-gen.ru
Rússia, Moscow
P. Apanovich
Research Center for Medical Genetics
Email: karpukhin@med-gen.ru
Rússia, Moscow
A. Markova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: karpukhin@med-gen.ru
Rússia, Moscow
B. Kamolov
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: karpukhin@med-gen.ru
Rússia, Moscow
V. Matveev
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation; M. V. Lomonosov Moscow State University
Email: karpukhin@med-gen.ru
Rússia, Moscow; Moscow
A. Karpukhin
Research Center for Medical Genetics
Autor responsável pela correspondência
Email: karpukhin@med-gen.ru
Rússia, Moscow
Arquivos suplementares
